Global Inhaled Corticosteroid Market Size By Type (Beclomethasone Dipropionate, Budesonide), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Inhaled Corticosteroid Market was valued at USD 13.7 billion in 2023 and is projected to surpass USD 21.9 billion by 2031, growing at a CAGR of 6.2% during the forecast period from 2023 to 2031. This growth is primarily driven by the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Increasing air pollution levels, changing lifestyles, and growing geriatric populations are also fueling the demand for inhaled corticosteroids. The shift from systemic to targeted drug delivery methods, which minimize side effects and enhance patient compliance, is further supporting market expansion.

Drivers:

1. Rising Prevalence of Chronic Respiratory Diseases:

Asthma and COPD continue to affect hundreds of millions globally, with the WHO estimating over 3 million deaths from COPD alone in recent years. Inhaled corticosteroids are essential in long-term control therapy, making them a mainstay in disease management.

2. Growing Geriatric Population:

Aging populations are more susceptible to respiratory diseases, thereby increasing the demand for effective treatment options such as inhaled corticosteroids.

3. Technological Advancements in Inhalation Devices:

Improved delivery devices, such as dry powder inhalers (DPIs) and metered-dose inhalers (MDIs), are making corticosteroid delivery more efficient and patient-friendly.

Restraints:

1. Side Effects and Medication Adherence Issues:

Long-term use of corticosteroids can lead to side effects like oral thrush and hoarseness. Additionally, patient non-compliance due to improper inhaler technique or fear of steroids can impact treatment outcomes.

2. Stringent Regulatory Guidelines:

The introduction of new formulations and inhalation devices is subject to rigorous approval processes, which may delay product launches and market entry.

Opportunity:

1. Expanding Access in Emerging Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are witnessing improved healthcare infrastructure, increased awareness of respiratory diseases, and better insurance coverage—factors that provide significant growth opportunities.

2. Personalized Medicine and Combination Therapies:

There is a growing trend toward developing fixed-dose combinations of inhaled corticosteroids with long-acting beta-agonists or muscarinic antagonists. Personalized treatment regimens tailored to patient-specific biomarkers are also emerging as a key opportunity area.

Market by System Type Insights:

By system type, the Metered-Dose Inhalers (MDIs) segment accounted for the largest market share in 2023. MDIs are preferred for their affordability and widespread use across both developed and developing regions. However, Dry Powder Inhalers (DPIs) are expected to witness the fastest growth due to their environmental friendliness (CFC-free), ease of use, and growing preference in pediatric and geriatric populations.

Market by End-use Insights:

In 2023, the Hospitals and Clinics segment held the largest market share, driven by the high volume of patients seeking diagnosis and treatment for respiratory conditions in institutional settings. Meanwhile, the Homecare Settings segment is anticipated to grow rapidly, fueled by the increasing adoption of home-based therapy, particularly among elderly and chronic disease patients.

Market by Regional Insights:

North America dominated the global inhaled corticosteroid market in 2023, supported by high healthcare spending, a well-established reimbursement structure, and a large pool of chronic respiratory disease patients. Asia-Pacific is forecasted to grow at the fastest CAGR, fueled by rising awareness, rapid urbanization, and government initiatives aimed at managing chronic respiratory diseases.

Competitive Scenario:

Leading players in the Global Inhaled Corticosteroid Market include:

GlaxoSmithKline plc

AstraZeneca plc

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Cipla Ltd.

Novartis AG

Boehringer Ingelheim International GmbH

Mylan N.V.

Sun Pharmaceutical Industries Ltd.

Orion Corporation

These companies are focusing on strategic partnerships, pipeline development, and regulatory approvals to maintain a competitive edge.

Scope of Work – Global Inhaled Corticosteroid Market

Report Metric Details

Market Size (2023) USD 13.7 billion

Projected Market Size (2031) USD 21.9 billion

CAGR (2023-2031) 6.2%

Market Segments By System Type (MDIs, DPIs, Nebulizers), By End-use (Hospitals, Homecare), By Region

Growth Drivers Rising respiratory disease prevalence, aging population, tech advancements

Opportunities Emerging markets, personalized medicine, combination therapies

Key Market Developments:

2023: GlaxoSmithKline launched a next-generation DPI formulation combining fluticasone and vilanterol for improved patient outcomes.

2024: AstraZeneca received FDA approval for a triple-combination inhaler for COPD management.

2025: Cipla announced the expansion of its inhalation drug portfolio across Southeast Asia and Africa, tapping into underserved respiratory markets.

FAQs:

1) What is the current market size of the Global Inhaled Corticosteroid Market?

The market was valued at USD 13.7 billion in 2023.

2) What is the major growth driver of the Global Inhaled Corticosteroid Market?

The rising prevalence of chronic respiratory diseases like asthma and COPD is the primary driver.

3) Which is the largest region during the forecast period in the Global Inhaled Corticosteroid Market?

North America leads the market, though Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in the Global Inhaled Corticosteroid Market?

The Metered-Dose Inhalers (MDIs) segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Inhaled Corticosteroid Market?

Key players include GlaxoSmithKline, AstraZeneca, Merck, Teva, Cipla, and others.